查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869813

肾臟病市场规模、份额和趋势分析报告：按检测类型、应用、最终用途、地区和细分市场预测（2025-2033 年）

Preeclampsia Market Size, Share & Trends Analysis Report By Test Type (Blood Test, Urinalysis), By Application Universal Screening, Targeted Testing, By End Use (Hospitals, Diagnostic Centers), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肾臟病市场摘要

预计到 2024 年，全球肾臟病前症市场规模将达到 12.5 亿美元，到 2033 年将达到 27.3 亿美元。

预计从 2025 年到 2033 年，该市场将以 9.12% 的复合年增长率成长。推动市场成长的因素包括肾臟病率的上升，以及对早期、准确的诊断测试的需求不断增长，以便在病情恶化之前预测和管理风险。

全球每年约有1.4亿新生儿出生，光是美国每年就有约370万名新生儿出生。高达30%的妊娠会受到併发症的影响，包括早产、肾臟病前症和胎儿生长受限。 2025年4月，Mirvie宣布其简单的血液检测可以预测妊娠17.5至22週时发生肾臟病的风险，使临床医生能够对患者进行风险分层并儘早干预。肾臟病是一种妊娠高血压，影响全球约2%至8%的怀孕。它通常在怀孕20週后发生，诊断依据是器官功能障碍的征兆，例如高血压和蛋白尿。如果未能及时发现或治疗，子痫前症可能发展为子痫（抽搐）、HELLP症候群、胎盘早期剥离和其他严重併发症。据估计，肾臟病每年在全球造成约46,000例孕产妇死亡和500,000例胎儿及新生儿死亡。由于子痫前症是导致孕产妇和周产期发病率的重要因素，因此迫切需要更好的预防、诊断和治疗手段。

肾臟病是一种严重的高血压，在美国，大约每12至25例妊娠中就有1例发生子痫前期，且发生率呈上升趋势。诊断子痫前症需要满足妊娠20週后血压升高，并伴随器官损伤的指标，例如尿蛋白（提示肾臟损伤）。风险因素包括肾臟病病史、先前慢性糖尿病或高血压、初产。

近年来，珀金埃尔默等公司已将DELFIA Xpress sFlt-1试剂盒纳入其获得CE-IVD认证的妊娠高血压诊断产品组合。赛默飞世尔科技的BRAHMS生物标记检测（sFlt-1/PlGF）目前可用于妊娠高血压的检查室管理，提供精确的风险评估。随着无细胞RNA检测（Mirvie）和预测风险评分等新型分子检测技术的成熟和获得监管部门核准，市场有望拓展至更早期的产前护理领域。此外，人们对孕产妇健康的日益关注、新兴国家意识的提高以及对女性健康科技投资的不断增加，也进一步推动了全球市场的成长。

然而，这些技术的普及程度并不均衡。儘管需求庞大，但由于缺乏生物标记检测的基础设施、资金限制以及产前保健方面的差异，先进检测技术在资源匮乏地区并未广泛应用。世界卫生组织指出，现有指引的实施进展缓慢，硫酸镁在许多资源匮乏地区仍未充分利用。此外，在许多地区，新型诊断技术的市场渗透受到监管和报销障碍的限制。然而，随着成本的降低和检测方式（例如，照护现场和居家检体采集）的日益便捷，这些障碍有望得到缓解。

目录

第一章肾臟病市场：调查方法与范围

2.肾臟病市场：执行摘要

  • 市场概述
  • 测试类型和应用程式简介
  • 最终用途简介
  • 竞争格局概览

3.肾臟病市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场限制因素分析
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章肾臟病市场：检测类型估算与趋势分析

  • 肾臟病市场：检测类型差异分析
  • 血液检查
  • 尿液检查

第五章肾臟病市场：应用预测与趋势分析

  • 肾臟病市场：应用变化分析
  • 一般筛检
  • 针对性检测
  • 监测和復发监测

6.肾臟病市场：终端用户需求预测及趋势分析

  • 肾臟病市场：终端用途差异分析
  • 医院
  • 专科诊所
  • 诊断中心
  • 其他的

7.肾臟病市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争情势

  • 公司分类
  • 策略规划
    • 推出一种新的测试类型
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 主要企业市占率分析，2024 年
  • 公司热力图分析
  • 公司简介
    • Thermo Fisher Scientific
    • Revvity
    • Diabetomics, Inc.
    • F. Hoffmann-La Roche
    • Metabolomic Diagnostics Ltd.（Trinity Biotech）
    • Sera Prognostics
    • Siemens Healthineers AG
    • Bayer AG
    • Quidel Corp
    • EUROFINS NTD GENETICS
    • LABCORP
    • MPROBE'S
Product Code: GVR-4-68040-772-8

Preeclampsia Market Summary

The global preeclampsia market size was valued at USD 1.25 billion in 2024 and is expected to reach USD 2.73 billion by 2033, growing at a CAGR of 9.12% from 2025 to 2033. The market is driven by rising incidences of the preeclampsia and the rising demand for early and accurate diagnostic tests to predict and manage risks before symptoms grow.

Globally, there are near about 140 million births annually; in the U.S. alone, about 3.7 million births per year, of which up to 30 % of pregnancies are affected by complications (including preterm birth, preeclampsia, restricted growth, etc.). In April 2025, Mirvie highlighted that its simple blood test can predict preeclampsia risk in pregnancy as early as 17.5 to 22 weeks-helping clinicians stratify patients and intervene sooner. Preeclampsia is a hypertensive disorder of pregnancy that affects roughly 2 % to 8 % of pregnancies worldwide. It typically presents after 20 weeks of gestation, and is diagnosed by elevated blood pressure and signs of organ dysfunction such as proteinuria. If undetected or unmanaged, the condition can progress to eclampsia (seizures), HELLP syndrome, placental abruption, or other severe complications. Each year, preeclampsia is estimated to be responsible for about 46,000 maternal deaths and 500,000 fetal or newborn deaths globally. Because it contributes significantly to maternal and perinatal morbidity, there is strong demand for better preventive, diagnostic, and management tools.

Preeclampsia is a serious blood pressure condition in the U.S. that affects about 1 in 12 to 1 in 25 pregnancies and is on the rise. After 20 weeks of pregnancy, high blood pressure and indicators of organ damage, such as protein in the urine, which suggests kidney damage, are necessary for the diagnosis. A history of preeclampsia, pre-existing chronic diabetes or hypertension, and first-time pregnancy are risk factors.

In the recent year's companies such as PerkinElmer added DELFIA Xpress sFlt-1 kit to its CE-IVD pre-eclampsia product offerings. The Thermo Fisher BRAHMS biomarker assays (sFlt-1 / PlGF) are now marketed for preeclampsia management in labs, offering precise risk calculations. As new molecular tests, such as cell-free RNA assays (Mirvie) or predictive risk scores, mature and get regulatory approval, they will broaden the market's reach into earlier prenatal screening. The global market's growth is further supported by rising maternal health focus, growing awareness in emerging economies, and increased investment in women's health technologies.

Adoption is uneven, though. Despite their great need, advanced tests are not widely adopted in low-resource settings due to a lack of infrastructure for biomarker assays, financial limitations, and gaps in prenatal care. The WHO notes that even with guidelines, implementation lags and magnesium sulfate is still underutilized in many low-resource settings. Furthermore, in many areas, market penetration for novel diagnostics is slowed by regulatory and reimbursement barriers. However, these obstacles might lessen as costs come down and test formats (like point-of-care or home sampling) get easier.

Global Preeclampsia Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preeclampsia market based on test type, application, end use, and region:

  • Test Type Outlook (USD Million; 2021 - 2033)
  • Blood Tests
  • Urinalysis
  • Application Outlook (USD Million; 2021 - 2033)
  • Universal Screening
  • Targeted Testing
  • Monitoring & Recurrence Surveillance
  • End Use Outlook (USD Million; 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Preeclampsia Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test Type Segment
      • 1.1.1.2. Application Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Preeclampsia Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type and Application Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Preeclampsia Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Dynamics
    • 3.5.1. Market driver analysis
      • 3.5.1.1. Rising incidence of preeclampsia
      • 3.5.1.2. Increasing research and development activities
      • 3.5.1.3. Growth in government Initiatives and Screening Guideline
    • 3.5.2. Market restraint analysis
      • 3.5.2.1. High cost of advanced diagnostics test
  • 3.6. Market Restraint Analysis
  • 3.7. Porter's Five Forces Analysis
  • 3.8. PESTLE Analysis
  • 3.9. Pipeline Analysis

Chapter 4. Preeclampsia Market: Test Type Estimates & Trend Analysis

  • 4.1. Preeclampsia Market: Test Type Movement Analysis
  • 4.2. Blood Tests
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Urinalysis
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Preeclampsia Market: Application Estimates & Trend Analysis

  • 5.1. Preeclampsia Market: Application Movement Analysis
  • 5.2. Universal Screening
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Targeted Testing
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Monitoring & Recurrence Surveillance
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Preeclampsia Market: End Use Estimates & Trend Analysis

  • 6.1. Preeclampsia Market: End Use Movement Analysis
  • 6.2. Hospitals
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Specialty Clinics
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Diagnostic Centers
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Preeclampsia Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Preeclampsia Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. NEW TEST TYPE LAUNCH
    • 8.2.2. PARTNERSHIPS
    • 8.2.3. ACQUISITION
    • 8.2.4. COLLABORATION
    • 8.2.5. FUNDING
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Test Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Revvity
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Test Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Diabetomics, Inc.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Test Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. F. Hoffmann-La Roche
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Test Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Metabolomic Diagnostics Ltd.(Trinity Biotech)
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Test Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sera Prognostics
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Test Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Siemens Healthineers AG
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Test Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bayer AG
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Test Type Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Quidel Corp
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Test Type Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. EUROFINS NTD GENETICS
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Test Type Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. LABCORP
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Test Type Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. MPROBE'S
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Test Type Benchmarking
      • 8.5.12.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Preeclampsia Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 5 Global Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 6 Global Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Preeclampsia Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 9 North America Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 10 North America Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 13 U.S. Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Preeclampsia Market, By Test Type, 2018-2030, (USD Million)
  • Table 15 Canada Preeclampsia Market, By Application, 2018-2030, (USD Million)
  • Table 16 Canada Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 21 Europe Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 25 UK Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 26 UK Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 29 Germany Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 31 France Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 32 France Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 35 Italy Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 38 Spain Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 40 Sweden Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 41 Sweden Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 43 Norway Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 44 Norway Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 47 Denmark Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 49 Asia Pacific Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 54 Japan Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 56 China Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 57 China Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 59 India Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 60 India Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 63 Australia Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 65 Thailand Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 66 Thailand Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 69 South Korea Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 71 Latin America Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 73 Latin America Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 76 Brazil Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 79 Argentina Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 81 MEA Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 82 MEA Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 83 MEA Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 86 South Africa Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 92 UAE Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global preeclampsia market- Key market driver analysis
  • Fig. 7 Global preeclampsia market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global preeclampsia market - Porter's analysis
  • Fig. 10 Global preeclampsia market - PESTEL analysis
  • Fig. 11 Global preeclampsia market Test Type outlook key takeaways
  • Fig. 12 Global preeclampsia market: Test Type movement analysis
  • Fig. 13 Blood Tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Urinalysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Global preeclampsia market application outlook key takeaways
  • Fig. 16 Global preeclampsia market: application movement analysis
  • Fig. 17 Universal screening market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Targeted testing market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Monitoring & recurrence surveillance market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Global preeclampsia market end use outlook key takeaways
  • Fig. 21 Global preeclampsia market: end use movement analysis
  • Fig. 22 Hospitals market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Specialty clinics market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Diagnostic centers market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Other End-users market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Global Preeclampsia market: Regional movement analysis
  • Fig. 28 North America Preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 33 UK preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 34 Germany preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 35 France preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 36 Spain preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 38 Denmark preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 39 Sweden preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 40 Norway preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 41 Asia Pacific preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 42 Japan preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 43 China preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 44 India preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 45 South Korea preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 46 Australia preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 47 Thailand preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 48 Latin America preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 49 Brazil preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 50 Argentina preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 51 MEA preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 52 South Africa preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 53 Saudi Arabia preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 54 UAE preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 55 Kuwait preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 56 Strategy framework